CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Bortezomib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00250926
NCT00250926Phase 2Completed
CompareCT.gov

A Phase II Study of the Combination Bortezomib (Velcade, PS-341), Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia

Dana-Farber Cancer Institute·interventional·Posted Nov 9, 2005·Updated Apr 8, 2016

In Brief

A Phase 2 clinical trial evaluating Bortezomib, Dexamethasone, and 1 other intervention for Waldenstrom's Macroglobulinemia. Completed, enrolled 23 participants across 2 sites.

Detailed Summary

The purpose of this study is to find out if the combination of bortezomib (Velcade), dexamethasone (Decadron) and rituximab (Rituxan) is effective in treating Waldenstrom's macroglobulinemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWaldenstrom's Macroglobulinemia
CountriesUnited States
CollaboratorsBeth Israel Deaconess Medical Center, Millennium Pharmaceuticals, Inc.

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 9, 2005
Enrollment StartOct 1, 2005
Primary CompletionMar 1, 2007
Study CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 20.6 years ago

Interventions

Bortezomibdrug

Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles

Dexamethasonedrug

Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles

Rituximabdrug

Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles